ClinicalTrials.gg
CompletedNCT05407961Updated Mar 29, 2024

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of LY3532226 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-29.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
35th of 54
90 · median 159
Started
2022
with 2 others
Phase 1
15 of 54
none open now
Registered
45th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 35th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 1, and was the 45th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 16 weeks excluding screening period for each part, respectively.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes mellitus (T2DM) for at least 3 months before screening
  • Have the following glycosylated () levels at screening:

    1. HbA1c >/= 7.0% to \</= 10.0% for participants treated with diet and exercise alone and participants treated with metformin alone, and
    2. HbA1c >/= 6.0% to \</= 9.5% for participants treated with dipeptidyl peptidase inhibitor-4 (DPP-4) (with/without metformin) inhibitors and participants treated with metformin and sodium-glucose cotransporter-2 (SGLT-2) inhibitor
  • Participants treated with diet and exercise alone or on a stable dose of metformin for at least 3 months
  • Participants with body weight up to 150 kilograms (kg) and (BMI) of 23.0 to 45.0 kilograms per meter squared (kg/m²)
  • Male participants who agree to use effective methods of and female participants not of

Exclusion criteria

Exclusion Criteria:

  • Participants who have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
  • Have a abnormality
  • Have obesity induced by other endocrine disorders such as Cushing's syndrome or Prader-Willi syndrome
  • Are on any glucose-lowering medications other than metformin, SGLT-2 inhibitors and/or DPP4
  • Have received chronic systemic therapy (>2 weeks) in the past 6 months
  • Have an average weekly alcohol intake that exceeds 21 units per week (males 65 years of age or lesser) and 14 units per week (females and males 65 years of age or older)
  • Smoke more than 10 cigarettes, or cigarette equivalent, per day
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    LY3532226 + Dulaglutide (Part A)

    LY3532226 administered subcutaneously (SC) followed by dulaglutide administered SC.

    Drug: LY3532226 · Drug: Dulaglutide

  • Placebo comparator
    Placebo + Dulaglutide (Part A)

    Placebo administered SC followed by dulaglutide administered SC.

    Drug: Placebo · Drug: Dulaglutide

  • Active comparator
    Dulaglutide + Placebo (Part B)

    Dulaglutide administered SC in combination with placebo given SC.

    Drug: Placebo · Drug: Dulaglutide

  • Experimental
    LY3532226 + Dulaglutide (Part B)

    LY3532226 administered SC in combination with Dulaglutide given SC.

    Drug: LY3532226 · Drug: Dulaglutide

  • Experimental
    LY3532226 + Placebo (Part B)

    LY3532226 administered SC in combination with placebo given SC.

    Drug: LY3532226 · Drug: Placebo

Interventions

  • Administered SC.

  • DrugPlacebo

    Administered SC.

  • Administered SC.

    Also known as: Trulicity

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Week 16

  2. Part B: Change from Baseline in Total Clamp Disposition Index (cDI)

    Change from Baseline in Total cDI

    Time frame: Baseline up to Week 12

Secondary outcomes

  1. Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3532226

    PK: Cmax of LY3532226

    Time frame: Predose on Day 1 through Week 16

  2. Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3532226

    PK: AUC of LY3532226

    Time frame: Predose on Day 1 through Week 16

  3. Part B: Change from Baseline in Insulin Secretion Rate (ISR) from hyperglycaemic clamp

    Change from Baseline in ISR from hyperglycaemic clamp

    Time frame: Baseline through Week 12

  4. Part B: Change from Baseline in β-cell Glucose Sensitivity (GS) from hyperglycaemic clamp

    Change from Baseline in β-cell GS from hyperglycaemic clamp

    Time frame: Baseline through Week 12

  5. Part B: Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value

    Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value

    Time frame: Baseline through Week 12

  6. Part A & B: Change from Baseline in Fasting and Post meal Glucose during Standardized Mixed-meal Tolerance Test (sMMTT)

    Change from Baseline in Fasting and Post meal Glucose during sMMTT

    Time frame: Baseline through Week 16

  7. Part A & B: Change from Baseline in Glycosylated Haemoglobin (HbA1c)

    Change from Baseline in HbA1c

    Time frame: Baseline through Week 16

  8. Part A & B: Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT

    Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT

    Time frame: Baseline through Week 16

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung
    Neuss, 41460, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jan 2024, 19 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 19 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 7, 2022
StartActual
Jun 7, 2022
Primary completionActual
Jan 12, 2024
CompletionActual
Jan 12, 2024
Last update
Mar 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05407961
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Jun 7, 2022
Primary completion
Jan 12, 2024
Completion
Jan 12, 2024
Last update
Mar 29, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Macupatide · Dulaglutide

Start the discussion